Schizotypal Personality Disorder clinical trials
The registry lists 49 studies for Schizotypal Personality Disorder across more than 10 countries. 12 are recruiting or about to start. 27 of them are mainly about Schizotypal Personality Disorder (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-14.
Get an email when these change. Save the Schizotypal Personality Disorder studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital (3) · Northwell Health (3) · Icahn School of Medicine at Mount Sinai (3) · University Hospital, Brest (2) · Tages Onlus (2) · King's College London (2) · University of California, Los Angeles (2) · Centre Psychothérapique de Nancy (2)
What is being tested here
Drugs under test in Schizotypal Personality Disorder studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Acetylcysteine | 1 | 1 | 2 |
| Risperidone | 0 | 0 | 3 |
| Dihydrexidine | 0 | 0 | 2 |
| Guanfacine | 0 | 0 | 2 |
| Diazepam | 0 | 0 | 1 |
| Levodopa | 0 | 0 | 1 |
| Benserazide | 0 | 0 | 1 |
| Oxytocin | 0 | 0 | 1 |
| Aripiprazole | 0 | 0 | 1 |
| Pergolide | 0 | 0 | 1 |
Drug classes tested here Antipsychotics 4 · Dopamine agonists 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Nov 2026Effects of NAC on Symptoms of CHR Patients · Centre for Addiction and Mental Health
- Dec 2026Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial · University of California, Los Angeles
- Mar 2027EPI-MINN: Targeting Cognition and Motivation - National · University of Minnesota
Who these studies take
Of the 9 Schizotypal Personality Disorder studies recruiting now, 1 (11%) set no upper age limit and 8 (89%) stop at 75 or younger. 5 (56%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (22%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 8 (89%) | 8 (89%) |
| 40 | 4 (44%) | 4 (44%) |
| 50 | 3 (33%) | 3 (33%) |
| 65 | 2 (22%) | 2 (22%) |
| 75 | 1 (11%) | 1 (11%) |
| 85 | 1 (11%) | 1 (11%) |
Across all 49 studies, recruiting or not: 90% stop at 75 or younger and 88% at 65; 33% take children; 2% are for women only and 2% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Schizotypal Personality Disorder studies take
Of 20 interventional studies with no phase under Schizotypal Personality Disorder, half reached primary completion within 44 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 44 mo14–59 · 20 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 49 of 49. search them.
- Evaluation of Step-Based Care for Individuals at Clinical High Risk for PsychosisEnrolling by invitationNCT039700051 country
- Online Intervention To Improve MotivationNot yet recruitingNCT07157293Not applicable1 country
- Patientheque in Patients With a PsychosisRecruitingNCT05340348Not applicable1 country
- Semantic and Syntactic Computerized Analysis of Free SpeechRecruitingNCT035250541 country
- Effects of NAC on Symptoms of CHR PatientsRecruitingNCT05142735Not applicable1 country
- Immune Mechanisms of Antipsychotic Treatment ResponseRecruitingNCT066876941 country
- Early Intervention of Prodromal Schizophrenia Using an NMDA EnhancerRecruitingNCT05052853Phase 21 country
- Perception and Integration of Sensory Information in the Early Stages of PsychosisNot yet recruitingNCT07446569Not applicable1 country
- PS-Trauma - Development of Trauma Treatment for Patients With Co-morbid Psychotic Disorders and TraumasRecruitingNCT07242586Not applicable1 country
- Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis RiskRecruitingNCT05131035Not applicable1 country
- An Integrated Neurophysiological Approach Toward the Early Detection of Psychiatric DisordersRecruitingNCT068869451 country
- Evolutionary Systems Therapy for SchizotypyRecruitingNCT05710926Not applicable1 country
- The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode PsychosisCompletedNCT04916626Not applicable1 country
- Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for "Paranoia".CompletedNCT04902066Not applicable1 country
- EPI-MINN: Targeting Cognition and Motivation - NationalActive, not recruitingNCT05877716Not applicable1 country
- SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial DisabilitiesCompletedNCT06007105Not applicable4 countries
- Accelerated TMS in PsychosisSuspendedNCT05567848Phase 1/21 country
- Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy TrialActive, not recruitingNCT04338152Not applicable2 countries
- Effect of Immersive Virtual Reality-based Cognitive Remediation in Patients With Mood - or Psychosis Spectrum DisordersCompletedNCT06038955Not applicable1 country
- REtinal and VIsual Cortical Response in Early PSYchosisTerminatedNCT05167396Not applicable1 country
- Feasibility Trial of a Lifestyle Intervention for CHR-PCompletedNCT05532683Not applicable1 country
- Neurofeedback Training for High Risk PsychosisCompletedNCT03447548Not applicable1 country
- Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis RiskCompletedNCT06190483Not applicable1 country
- Feasibility of a Novel Process-based Treatment for Patients With PsychosisCompletedNCT04874974Not applicable1 country
- Effectiveness of Behavioral Activation Treatment for SchizophreniaStatus unknownNCT05764148Not applicable1 country
- Examining Dose-Related Effects of Oxytocin on Social Cognition Across PopulationsTerminatedNCT02149823Phase 11 country
- Compassion and Metacognition in Schizotypal PersonalityCompletedNCT04764708Not applicable1 country
- "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"TerminatedNCT03149107Phase 31 country
- The Development of a Screening Questionnaire to Discriminate Autism Spectrum Disorder and Schizotypal Disorder, and Validation of the Danish Version of RAADS-RStatus unknownNCT05213286Not applicable1 country
- Early Detection and Intervention for Women At-risk of PsychosisStatus unknownNCT03751865Not applicable1 country
- Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult SampleCompletedNCT028006811 country
- Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode PsychosisCompletedNCT03409393Not applicable1 country
- A D1 Agonist For Working MemoryCompletedNCT02507206Phase 21 country
- Exceptional Experiences (EE), Salience & Dopaminergic NeurotransmissionCompletedNCT03333369Early Phase 11 country
- Schizotypal Personality Disorder RisperidoneCompletedNCT02535156Phase 1/2
- CRT-Guanfacine for SPDCompletedNCT02524899Phase 21 country
- Pharmacology of Cognition in Schizotypal Personality DisorderTerminatedNCT00353379Phase 41 country
- Extended Specialized Assertive Intervention for First Episode PsychosisCompletedNCT00914238Not applicable1 country
- Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset SchizophreniaCompletedNCT01773239Not applicable1 country
- Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality DisorderCompletedNCT00158028Not applicable1 country
- Psychosis: Early Detection, Intervention and PreventionCompletedNCT01597141Not applicable1 country
- Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode PsychosisStatus unknownNCT00157313Not applicable1 country
- Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of PsychosisCompletedNCT01619319Not applicable
- Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) StudyCompletedNCT012697101 country
- Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality DisorderStatus unknownNCT01466205Phase 21 country
- Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative SymptomsCompletedNCT00169988Not applicable1 country
- Aripiprazole Treatment of the ProdromeTerminatedNCT00169949Not applicable1 country
- A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological DysfunctionsCompletedNCT00155519
- Pergolide for Cognitive Symptoms in Schizotypal Personality DisorderStatus unknownNCT00252044Not applicable1 country